Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

By Celestia S. Higano, Paul Schellhammer, E. Small, P. Burch, J. Nemunaitis, Lianng Yuh, Nicole M. Provost, M. Frohlich. Cancer, 2009

845 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/bf3f2b8ae3ba3ea29026ec334c9fe1b5448e055b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. K. Palucka
2. Jacques Banchereau
3. Celestia S. Higano
4. S. Farkona
5. Eleftherios P. Diamandis
6. I. Blasutig

In Oncology

1. K. Palucka
2. Jacques Banchereau
3. S. Farkona
4. Eleftherios P. Diamandis
5. I. Blasutig

In Pulmonary and Respiratory Medicine

1. Celestia S. Higano
2. M. Cheever
3. Eleftherios P. Diamandis

Citations in the corpus

• Cancer immunotherapy via dendritic cells (2012, positive): “gov/drugdictionary?CdrID=38038">sipuleucel-T (also known as APC 8015), which is a cellular product based on enriched blood APCs that are briefly cultured with a fusion protein of prostatic acid phosphatase (PAP) and GM-CSF, resulted in an approximately 4-month-prolonged median survival in Phase III”
• Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “(GM-CSF), achieved an approximately 4-month improvement in median survival [18, 19].”
• PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine (2011, background): “Phase III studies Two phase III studies (D9901 and D9902A) set the stage for the Immunotherapy Prostate Adenocarcinoma Treatment (IMPACT) trial, the pivotal study that led to FDA approval (13, 14).”